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including embryonic development, disease pathogene-
sis, nonspecific response to infection, specific antigen
responses, changes in cognitive function, and progres-
sion of the degenerative aging processes. In addition,
cytokines play roles in stem cell differentiation, vaccine
efficacy, and allograft rejection. This affect onmultiple
biological properties, or pleiotropism, is the hallmark
of a cytokine. This report provides an overview of
the failures and successes of cytokines as therapeutic
targets.
A recent advance is differential cytokine produc-
tion, which can be used to classify human disease as be-
ing ‘‘autoimmune’’ or ‘‘autoinflammatory’’ and thereby
guide therapeutic interventions. Cytokines wreak
havoc with the immune system, turning the system
against itself in autoimmune diseases. During infec-
tion, the cytokine ‘‘storm’’ subsides as the infection is
eliminated and the genes return to their normal state
of repression by histone acetylases. When the cytokine
genes fail to shut down, their products drive the host
into a state of chronically activated cells, which now
dominate an otherwise resting immune system. Autor-
eactiveT cells are cells that persist and fail to die.Other
genetically influenced ‘‘failure to die’’ mechanisms
likely contribute to this persistence as well. Most anti-
cytokine therapies for autoimmune disease target the
effects of cytokines on inflammatory and tissue remod-
eling processes but seem unable to shut down the
persistently activated autoreactive T cells.
The use of agents that specifically block the activity
of a cytokine truly defines the role of that cytokine in
disease or in an immunologic response. Although the
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kines in the pathogenesis or progression of disease,
approval for the use of these agents in humans remains
the ultimate goal.
The same agents that failed in clinical trials for sep-
sis were tested in patients with rheumatoid arthritis,
Crohn’s disease, and plaque psoriasis. In the case of
blocking tumor necrosis factor (TNF)-a, monoclonal
antibodies to TNF-a and soluble TNF receptors have
been highly successful in treating these autoimmune
diseases, having been used in more than 800,000 pa-
tients. As a result, nearly every anticytokine agent,
whether an orally active inhibitor of a cytokine-regulated
intracellular pathway, a neutralizing antibody, a soluble
receptor, or a receptor antagonist, has been tested in
patients with rheumatoid arthritis, Crohn’s disease,
or psoriasis. Blocking of interleukin (IL)-1, IL-6,
IL-12, and IL-23 has been successful, whereas blocking
of IL-15 or IL-18 has beenmarginal. In general, animal
models can predict which cytokines are likely to im-
prove rheumatoid arthritis and Crohn’s disease [1]
but cannot predict which anticytokine will be effica-
cious for a specific patient.
Autoimmune diseases included both dysfunctional
immune responses and a prominent inflammatory com-
ponent. Other chronic diseases appear to be mostly in-
flammatory in nature and associated with dysregulation
of IL-1b processing and secretion. These diseases are
designated autoinflammatory to distinguish them
from autoimmune diseases. Examples of autoinflamma-
tory diseases include familial Mediterranean fever,
neonatal-onset multiple system inflammatory disease,
and systemic-onset juvenile idiopathic arthritis. Patients
with these diseases suffer from chronic fever, systemic
inflammation, and joint pain. Rapid reversal of disease
severity occurs after the blocking of IL-1b activity.
Thepathological abnormality in autoinflammatory
diseases appears to be a failure to control IL-1b pro-
cessing and secretion. Release of active IL-1b from
bloodmonocytes is increased in patients with these dis-
eases. The processing and secretion of IL-1b is con-
trolled by caspase-1, an intracellular cysteine protease
that cleaves the IL-1b precursor, as well as IL-18 and
Biol Blood Marrow Transplant 15:134-136, 2009 135Inflammation in Human Disease: Anticytokine TherapyIL-33 precursors, into active cytokines. Caspase-1 is
controlled by the caspsase-1 inflammasome, a complex
of intracellular proteins. The discovery of inflamma-
somes is one of the hallmarks of cytokine biology;
inflammasome-mediated processing regulates the in-
flammation mediated by IL-1b, IL-18, and IL-33.
Most cytokines function solely by binding to spe-
cific cell surface receptors, which initiates a cascade of
intracellular signals affecting gene expression mediated
by transcription factors, such as nuclear factor kappa
light-chain enhancer of activated B cells (NF-kB) and
activator protein 1 (AP-1). Increasing evidence indicates
that some cytokines function as classic ligands for spe-
cific receptors and also have another life as transcription
factors; for example, the N-terminal amino acids of the
IL-1b precursor binds to DNA and participates in tran-
scriptional machinery [2], whereas the carboxyl domain
(mature) binds to the IL-1 cell surface receptor and
induces the same portfolio of genes as IL-1b does.
High-mobility group B-1 (HMGB-1), a nuclear
DNA-binding protein that regulates gene transcription
and steroid hormone receptors, binds to the receptor
for advanced glycation endproducts (RAGE) and func-
tions as a proinflammatory cytokine, inducing IL-1b
and TNF-a [3]. Antibodies to HMGB-1 reduce disease
severity in animal models of inflammation. It is likely
that the original functions of these immune and inflam-
matory responses were in signaling, but these cytokines
appear to have other functions as well. For example,
IL-33, the specific ligand for the IL-1 family receptor
ST2, is a Th2 cytokine; however, IL-33 is homologous
to the nuclear factor high endothelial venules (NF-
HEVs) binding chromatin [4]. Chromatin binding
and transcriptional repression are due to theN-terminal
domains of IL-33, whereas the C-terminal part of the
molecule is homologous to IL-1. Interferon (IFN)-g
has intracellular targets.
There is no dearth of reports on the association be-
tween circulating cytokines and disease severity. De-
spite highly statistically significant correlations, an
important lesson in cytokine biology is that a causative
role of a particular cytokine in disease can be estab-
lished only by specific blockade in animals or humans.
For example, serum IL-6 levels often correlate with
mortality in patients with septic shock, but the admin-
istration of high doses of IL-6 to humans does not
affect blood pressure or the other physiological param-
eters of shock. On the other hand, nanogram-per-kg
doses of IL-1 or TNF-a injected into humans induces
life-threatening hypotension [5], yet few studies have
attempted to correlate serum levels of IL-1 or TNF-
a with any disease. In the past decade, another prop-
erty of cytokines has emerged—their action as both
an extracellular molecule engaging its specific cell sur-
face receptor and an integral membrane protein that
uses a juxtacrine mechanism of cell–cell contact for
its activity [6]. For example, a considerable amountof the biological activity of TNF-a in rheumatoid ar-
thritis and Crohn’s disease likely is mediated by mem-
brane TNF-a. It is likely that many of the effects of
cytokines occur in the microenvironment [7], whereas
systemic levels of cytokines, such as IL-6, are primarily
markers of disease severity.
As more cytokines were discovered, it became clear
that some cytokines had proinflammatory properties
and others inhibited inflammation. The message was
that nature has provided mechanisms to limit or balance
exuberant cytokine responses. For example, soluble
receptors [8,9] and decoy receptors [10] limit the cyto-
kine action of their respective ligands. Cytokines with
anti-inflammatory and immunosuppressive properties
include IL-4, IL-10, IL-22, and transforming growth
factor b. Even IL-6 appears to reduce inflammation;
IL-6–deficient mice exhibit greater inflammation pro-
duce higher levels of TNF-a than wild-type mates.
Toll-like receptor agonists induce both proinflammatory
and antiinflammatory cytokines, and IL-10–deficient
mice develop spontaneous inflammatory bowel disease.
Mice deficient in IL-1 receptor antagonist spontaneously
develop inflammatory arthritis and arteritis [11]; without
this antagonist, these mice have no counterbalance
against the effects of IL-1b.
Another mechanism for controlling inflammation
or during an immune response is suppression of cyto-
kine signaling (SOCS). Increased inflammation and
immune responses are observed in the absence of these
gene products. But perhaps the most common mecha-
nism for controlling runaway immune stimulation or
inflammation is the effect of prostaglandins on cyto-
kine production and cytokine activity. Prostaglandin
E (PGE) 2 is perhaps the most potent suppressor of
T cell function; PGE2-induced cyclic adenosine
monophosphate inhibits the production of IL-2,
IFN-g, TNF-a, and other cytokines. Many persons
routinely use aspirin and other inhibitors of cyclo-
oxygenase (COX)-1 or -2, which affect cytokine
responses, particularly immune responses. A short
course of daily aspirin increases the production of
IFN-g from primary human bloodT cells [12]. In con-
trast, PGE2 augments the production of IL-6. Oral
COX inhibitors reduce serum IL-6 and acute-phase
proteins in patients with rheumatoid arthritis. The dis-
covery that nutritional status and the balance between
cell membrane composition of N-3 andN-6 fatty acids
affect cytokine production and activity [13] likely
explains the large body of epidemiologic evidence on
the dietary affects on health, disease, and the aging
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